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Importance of the field: The endothelin (ET) axis, which includes the biolog-
ical functions of ETs and their receptors, has played a physiological role in
normal tissue, acting as a modulator of vasomotor tone, tissue differentiation
and development, cell proliferation and hormone production. Interestingly, it
also functions in the growth and progression of various tumors. Several
researchers have identified the blockade of the ET-1 receptor as a promising
therapeutic approach.
Areas covered in this review: The clinical investigation of an orally bioavail-
able ET antagonist, atrasentan, in prostate cancer, is encouraging. In this
neoplasia, it has shown antitumor activity, bone metastasis control and
amelioration of cancer-related pain but improvement in time to progression
and overall survival has still not been demonstrated. The clinical trials of other
ET antagonists are reported. Literature research was performed by Pubmed
and Pharmaprojects.
What the reader will gain: A comprehensive view about the use of atrasentan
in the treatment of castration-resistant prostate cancer (CRPC) is provided
together with the scientific rationale based on the function of ET and its
receptor in various cancer development mechanisms.
Take home message: Atrasentan seems to be active in CRPC, although
strong scientific evidence is still to be found. Interesting clinical findings
regard zibotentan.
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1. Background
The endothelins (ETs), discovered by Yanagisawa in 1988, are a family of small
peptides, well conserved from the evolutionary aspect, with multiple roles in a
variety of tissues [1]. Initially, ET was thought to be important in cardiovascular
homeostasis; ET receptor antagonists and endothelin-converting enzyme (ECE)
inhibitors have, therefore, been developed mostly for the treatment of cardiovascular
diseases. Molecular biology has also provided valuable information about ET,
including evidence that the ET system plays an important role in the early
development of the neural crest and, thus, in the formation of organs [2].
At present, the ET system, which comprises ETs, their receptors and the enzymes
of ET biosynthesis and degradation, is thought to have a role in the pathophysiology
of many tumor types, including prostatic, pulmonary, cervical, endometrial, ovarian,
colorectal, breast, bladder, renal and brain tumors, Kaposi’s sarcoma, bone metas-
tases and melanoma [3-5]. In mammals, the ETs comprise a family of three 21 amino-
acid peptides, ET-1, ET-2 and ET-3, whose structure consists of a single a-helix and
two intramolecular disulfide bonds. Whereas ET-1 and ET-2 have similar structures,
ET-3 differs in structure at 6 of 21 amino acids. ET-1 is not organ-specific and is
expressed primarily by endothelial cells, whereas ET-2 is mainly present in the
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intestine and kidney, and ET-3 is mainly localized in the brain
and to a lesser extent in gastrointestinal stromal cells and lung
epithelial cells [4].
The ETs are encoded by distinct genes and are regulated at
the level of mRNA transcription and post-transcription [1].
The primary translation product of the mRNA of ET-1 gene is
the 212-aa prepro-ET-1. Active ET-1 is synthesized from a
biologically inactive 38-aa precursor, Big ET-1, by an unusual
hydrolysis of the Trp21–Val22 bond by a metalloprotease
with intracellular and membrane bound isoforms, known as
the ECE-1 [6,7]. The mature peptide is continuously released
from vascular endothelial cells by the constitutive pathway,
producing intense constriction of the underlying smooth
muscle and contributing to the maintenance of endogenous
vascular tone. Several studies of various malignancies have
revealed that members of the ET family are produced by
several epithelial tumors, in which they act as autocrine and/or
paracrine growth factors. ET-1 is the most common
circulating form of ET [8].
ETs are powerful vasoconstrictive peptides that exert their
effects through two specific heptahelical GPCR subtypes: the
endothelin A receptor (ETAR) specific for ET-1 and ET-2 and
the nonspecific endothelin B receptor (ETBR) [1,9,10]. The ET
receptors share about 59% similarity in the primary structure.
The ETAR selectively binds ET-1 and ET-2, whereas the
ETBR binds all three ET forms with similar affinity. While the
ETAR primarily mediates vaso-/bronchoconstriction, mito-
genesis, antiapoptosis, matrix formation, acute and neuro-
pathic pain, the ETBR mediates inflammatory pain and
vasodilatation and has further been proposed to contribute
to clearance of ET as well as to autoinduction of ET-1 [11].
Although the ETBR may also mediate vasoconstriction, this
subtype, which is primarily situated at the plasma membrane
of endothelial cells, is first of all considered causing transient
NO-mediated vasodilatation. The ETBR shares several intra-
cellular signaling pathways with the ETAR; however, unlike
ETA receptor-dependent effects, ETBR-dependent phenom-
ena are shorter lasting and reversible. ET receptor interacts
with heterotrimeric G proteins. After ligand binding, ETARs
become internalized and undergo receptor recycling followed
by relocation to the cell membrane, whereas ETBRs can be
translocated to the lysosomal compartment for degradation [12]
or translocated to nuclear membranes for further signaling
events [13]. ETs and ET receptors are ubiquitously expressed
and regulate a wide range of physiological and pathophysio-
logical functions, such as cardiovascular, mitogenic and neu-
roregulatory events, hormone production and placental
development [14].
ET-1 production is stimulated by cytokines (IL-1h), growth
factors (TNF-a, TGF-h and platelet-derived growth factor
(PDGF)) and major signals of cardiovascular stress, such as
vocative agents (angiogenesis II, norepinephrine, vasopressin
and bradykinin), thrombin, mechanical stress and hypoxia.
Prostacyclin, NO and atrial natriuretic peptide are the
predominant effectors of negative feedback mechanisms [15].
2. Medical need
Nearly all patients with advanced prostate cancer are sen-
sitive to androgen ablation therapy. However, the effect of
this treatment on disease progression is temporary. These
patients ultimately become resistant to androgen ablation
and are then classified as having castration-resistant prostate
cancer (CRPC). To date, chemotherapy is the main option
for this disease. Docetaxel represents the best tolerated and
effective agent of treating it.
There has been great interest regarding the possibility of
using this drug for the treatment of even elderly patients,
because prostate cancer apparently occurs more frequently in
older men. An intravenously delivered chemotherapeutic
agent with high incidence of hematological toxicity, even
if better tolerated than other drugs with the same clinical
indication, such as docetaxel, may hinder the accessibility of
comorbid patients. For several years, oncologists have been
trying to find new agents with minimal toxicity to be
administered per os.
Another hurdle for these patients is the development of
resistance to docetaxel. When CRPC patients progress after
first-line therapy, there are only a few options available for
their treatment. New types of therapy are required in this
patient setting. The effect of ET receptor antagonists on
angiogenesis might be exploited to overcome taxane resistance.
3. Existing treatment
Treatment with hormone therapy or chemotherapy is the
standard option for patients with CRPC. After progression on
both a luteinizing-hormone-releasing hormone agonist and
antiandrogen, the withdrawal of antiandrogen therapy results
in an antiandrogen withdrawal response in 25 – 50% of
patients. Secondary hormone medications, including ketoco-
nazole and hydrocortisone, could induce a clinical response in
~ 25% of patients. This benefit lasts for only a short time, with
a mean duration of 4 months. For this reason, chemotherapy
is considered the main choice for such patients. The devel-
opment of novel therapeutic agents for the treatment of CRPC
is still to be explored in this patient population.
Combination chemotherapy regimens involving agents that
affect microtubule integrity appear to have activity with
tolerable adverse effects. In particular, combination regimens
including taxanes seem the most promising treatment, achiev-
ing > 50% response rates. However, the median duration of
response is limited to ~ 6 months. Additional survival benefits
reported in Phase II trials have not yet been confirmed in
Phase III randomized trials.
Because of the increasing proportion of patients included in
earlier application of taxane-based chemotherapy, there is an
ever enlarging subset of patients with disease progression who
remain viable candidates for additional therapy. To date, we
lack enough data from clinical trials to guide decision making,
although clinical investigation is ongoing for this subset of
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patients. Usually, CRPC patients previously treated with
first-line chemotherapy are classified into two groups:
mitoxantrone-treated patients, for whom the utility of taxanes
as second-line therapy should be considered, and taxane-
treated patients, for whom the activity of retreating with
taxanes, mitoxantrone or other microtubular targeted agents
is under investigation.
ET receptor antagonists studied for cancer treatment are
not yet marketed.
A previous US registration submission as Xinlay for the
treatment of metastatic CRPC received a non-approvable
letter (Scrip Daily Online, 17 October 2005, S00899072).
Abbott decided not to pursue further registration of astrasen-
tan for this indication (direct communication, Abbott,
24 August 2007). It had US fast-track status for prostate
cancer (press conference, Abbott, 6 February 2001).
Regarding Zibotentan, European and US filings for the
treatment of CRPC are expected in 2011 (company pipeline,
AstraZeneca, 31 January 2008).
4. Current research goals
The main goals of treatment with ET receptor antagonists for
CRPC patients include:
. Availability of agents with minimal or manageable toxicity
and orally bioavailable to extend applicability of anticancer
treatment even for elderly and comorbid patients.
. Efficacy on cancer-related pain and bone metastases com-
plications, which are the most frequent factors impairing
quality of life.
. Applicability also in nonmetastatic CRPC to improve
both progression-free survival and overall survival and
to delay major complications deriving from clinically
evident metastases.
The great hope of the researchers regards the prospect of
using ET receptor antagonists even in other malignancies.
Until now, no clear evidence has been provided for activity of
these agents in different cancers. A better understanding of the
biological mechanisms of their action will make it possible to
investigate them in a more suitable patient setting.
5. Scientific rationale
5.1 Role of ET-1 in cell growth
ET-1 is a powerful vasoconstrictor with mitogenic or co-
mitogenic properties, which stimulates proliferation in vitro of
fibroblasts, renal mesangial cells, smooth muscle and
several tumor cell lines, including colorectal cancer [16-20].
Studies involving colorectal, ovarian and prostate cancers
suggest that the receptor responsible for the ET-1 mitogenic
action is ETA, which is probably upregulated. Activation of
the ETAR by ET-1 mediates a signaling cascade, which
promotes tumor cell growth, synergizing with other growth
factors to cause cell proliferation (Figure 1). ETA interacts with
and activates a G protein that triggers a parallel activation of
several signal transducing pathways. This interaction can in
fact activate multiple signal transduction pathways including
phospholipase C activity with a consequent increase in
intracellular Ca2+ levels, PKC, phosphati-dylinositol 3-kinase
and MAPK [21]. ETBR-mediated coupling in choriocarcinoma
cell lines leads to the activation of the Ras/Raf-MAPK path-
way [22]. ET-1 causes EGFR transactivation which is partly
responsible for MAPK activation by a ligand-dependent
mechanism involving a non-receptor tyrosine kinase, such
as Src. Recent work has reported that a specific ETAR
antagonist can reduce the EGFR transactivation [14,23-25].
The phenotypic change of vascular smooth muscle cells in
culture is concommitantly associated with a change in the ET
receptor subtype which potentiates mitogenic activity. This
suggests that the switching of the ET receptor subtype from A
to B during phenotypic change may contribute to a certain
extent to the development of vascular lesions [26].
ET-1 promotes DNA synthesis and cell proliferation in
various epithelial tumor cells, including prostate, cervical and
ovarian cancer cells. Synergistic interactions with other growth
factors, including EGF, basic fibroblast growth factor (bFGF),
insulin, IGF, PDGF, TGFs and IL-6, intensify mitogenic
activity [27].
5.2 Role of ET-1 in angiogenesis
Angiogenesis, the formation of new vessels from existing
vasculature, is an important early event in tumor progression
which begins in premalignant lesions. VEGF and bFGF are
the principal regulators of neovascularization. During the
formation of new blood vessels, endothelial cells are stimu-
lated to release proteases, such as MMP-2, in order to migrate,
proliferate and invade surrounding tissue and form capillaries.
Initiation of angiogenesis is controlled by different regulators
including local hypoxia, which activates the expression of
angiogenic factors that can stimulate endothelial cell
growth [28]. Activation of ETAR by ET-1 promotes tumor
growth and progression by stimulating the production of the
key angiogenic factor VEGF in response to hypoxia. ET-1
regulates various stages of neovascularization, including endo-
thelial cell proliferation, migration, invasion, protease
production and tube formation, and also stimulates neovas-
cularization in vivo [29]. ET-1 increases VEGF mRNA expres-
sion and VEGF protein levels in a dose- and time-dependent
manner, and does so to a greater extent under hypoxia. ET-1
stimulates VEGF production through the hypoxia-inducible
factor HIF-1a and this mechanism might be responsible for
increasing tumor angiogenesis. Degradation of HIF-1a is in
fact reduced in ET-1-treated ovarian carcinoma cells under
both hypoxic and normoxic conditions, indicating that the
induction of HIF-1a protein production by ET-1 is due to
enhanced HIF-1a stability. After ETAR activation by ET-1,
HIF-1a protein levels are increased, the HIF-1 transcription
complex is formed and binds to the hypoxia-responsive
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element binding site [3]. Furthermore, not only does ET-1
stabilize HIF-1a under hypoxic and normoxic conditions,
inducing the transcription of angiogenic genes, but HIF-1a is
also able to modulate transcription of ET-1 in various cell
types. Moreover, the ETAR blockade exerts an antiangiogenic
effect by completely inhibiting growth and neoangiogenesis in
different tumors [30].
Prostaglandins (PG) and their rate-limiting enzymes
COX-1 and -2 are involved in the progression of a variety
of malignancies in association with elevated levels of
proangiogenic factors [31-33].
Under normoxic condition, ET-1 significantly stimulates
the expression of COX-1 and -2 at mRNA and protein levels,
COX-2 promoter activity and prostaglandin PGE2 produc-
tion. PGE2 promotes angiogenesis and this effect is mediated
by VEGF. The use of EP agonists and antagonists indicates
that ET-1 and PGE2 stimulate VEGF production, principally
via two receptors, EP2 and EP4.
5.3 Role of ET-1 in apoptosis
Apoptosis is an active cell death process that takes place in a
wide spectrum of physiologic situations such as normal cell
turnover, embryogenesis and endocrine-dependent tissue
atrophy.
Recently, investigations into the role of the ET axis in
apoptosis inhibition have provided evidence of the importance
ECE
NEP
Prepro-ETs
ET-1 ET-2 ET-3
ETAR ETBR
G-protein
PLC PKC PI3K MAPK
Cell
migration
Cell
proliferation
AngiogenesisEvasion
of apoptosis
ET clearanceAutoinduction
of ET-1
AngiogenesisInflammatorypain
Figure 1. Molecular mechanisms of endothelin axis.
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of the ET-1 axis in cell survival. Previous studies have
indicated a potential function for ET-1 in cell proliferation
or as a cell survival factor.
Interaction between the Fas receptor (CD95/APO-1), a
member of the TNF-receptor superfamily, and the Fas ligand
(FasL) triggers a pathway to cell death involving caspase-8
activity. However, despite expression of Fas and caspase, death
signals are frequently interrupted by also anti-apoptotic mod-
ulators, including caspase inhibitory proteins such as FLIP [34].
In human glioblastoma cell lines, ET-1, acting as survival
factor, probably acts through ERK phosphorylation and the
PKC pathway, determining a stabilization of the short form
of FLIP protein [35]. The binding of ET-1 to high-affinity sites
inhibits FasL-induced apoptosis, while the binding of either
ET-1 or receptor antagonists to low-affinity sites promotes
FasL-induced apoptosis. Thus, ET signaling pathways do not
induce human cancer cell proliferation, but are survival signals
controlling resistance to apoptosis [36].
As these effects are mediated by ETAR, activation of ETB by
ET-1 conversely induces cell death via apoptosis in human
cancer cells [37].
In ovarian carcinoma cells, the addition of ET-1 signif-
icantly inhibits paclitaxel-induced apoptosis in a dose-
dependent fashion as a result of Bcl-2 phosphorylation
suppression. ET-1 also stimulates Akt activation in a
PI3K-dependent manner. Interestingly, the use of specific
ETAR antagonists has demonstrated that ET-1 contributes
to paclitaxel resistance through ETAR binding via activation
of anti-apoptotic signaling pathways [21].
5.4 Role of ET-1 in tumor invasiveness
Tumor invasion is characterized by changes in MMPs, con-
nexin, integrin and cadherin expression. The presence of high
levels of ET-1 in ascitic fluids of ovarian cancer patients has
shown that ET-1 may increase the secretion of extracellular
matrix-degrading proteinases and metastatization process. In
fact, ETAR activation induces matrix-degrading enzymes, such
as MMPs and urokinase plasminogen activator, which play
important roles in tissue remodeling and tumor metastasis [38].
The ET-1 system acts by enhancing the invasive potential
of tumor cells. ET-1, in fact, activates MMP-2, MMP-3,
MMP-7, MMP-9 and MMP-13. EP2 and EP4 receptor
antagonists block MMP activity and cell invasion, dem-
onstrating that these receptors are the principal PGE2
receptors involved in these processes [39]. Furthermore,
ET-1 stimulates focal adhesion kinase (FAK) and paxillin
phosphorylation through the ETAR, which directly corre-
lates with tumor cell migration and invasion [24]. This indi-
cates that ETAR antagonists can inhibit cell migration and
possibly other FAK-associated processes.
Defects in regulation of intercellular communication, such
as dysregulated or reduced expression of connexins, allow
cancer cells to escape microenvironmental control from the
normal surrounding tissue. ET-1 is able to disrupt gap
junctions and this might serve as a basis to further evaluate
the cell–cell metabolic uncoupling and the cell detachment
that occurs during tumor progression [40]. In epithelial cancer,
the loss of the epithelial features and the gain of a mesenchy-
mal phenotype, a process known as epithelial to mesenchymal
transition (EMT), determine the acquisition of tumor inva-
siveness. A primary event regulating EMT is the disruption of
the E-cadherin-mediated stable interactions between the cells.
In ovarian carcinoma cells, activation of the ETAR pathway by
ET-1 contributes to disruption of normal host–tumor inter-
actions by downregulating the expression of E-cadherin and
associated b-catenin adhesion proteins [41]. ET-1 induces
expression of the transcription factor Snail, which has been
identified as a potent repressor of E-cadherin expression.
5.5 Role of ET-1 in osteogenesis
The ET axis seems to have a central role in osteoblastic bone
metastasis. Alkaline phosphatase, a marker of new bone
formation, is elevated in the presence of exogenous ET-1 [42].
ETA and ETB appear to regulate tumor progression by a
mechanism involving bone deposition in skeletal metastases
through the activation of osteoblasts. It is thought that ET-1
production by metastatic cancer cells located in the bone is
stimulated by osteoblast- and endothelial cell-secreted IL-1,
TNF-a and TGF-h. ET-1, in turn, would stimulate mitotic
activity in osteoblasts, decreasing both osteoclastic bone
resorption and osteoclast motility [43,44]. Several experiments
conducted in human prostate cancer cell lines have shown that
osteoclastic bone resorption is significantly blocked by the
presence of ET-1 in a dose-dependent fashion. In prostate and
breast cancer models, selective ETAR inhibition, but not
ETBR modulation, suppressed ET-1-induced osteoblastic
response [45,46]. It seems that a calcineurin/FAT (nuclear factor
of activated T cells) pathway is involved in the molecular
mechanism of ET-1-mediated osteoblast stimulation.
5.6 ET receptor antagonists’ preclinical development
ET-1 has shown pleiotropic mechanisms in different pathways
of cancer development and progression. For this reason, many
researchers have hypothesized a role of the ET-1 axis targeting
for cancer treatment. Various approaches have been identified
in order to impair ET biological function in tumors, for
example, inhibition of ET biosynthesis, blockade of ET
production from preproETs, promotion of ET degradation,
selective blockade of ETAR/ETBR activation and enhance-
ment of tumor perfusion by ETBR activation to potentiate
efficacy of antineoplastic drugs.
Red wine polyphenols (i.e., quercetin, resveratrol, cathe-
chins, etc.) can suppress ET-1 release and the transcription of
prepro-ET-1 gene [47]. Similarly, green tea polyphenol epi-
gallocatechin-3-gallate in ovarian carcinoma cells and xeno-
grafts have inhibited both ETAR and ET-1 expression and
reduced basal and ET-1-induced cell proliferation and
invasion [48]. ET synthesis might be blocked by inhibition
Russo, Bronte, Rizzo, Fanale, Di Gaudio, Gebbia & Bazan
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of the enzyme which converts preproETs into ETs. ECE
inhibitors have been studied for various cardiovascular,
renal, pulmonary and neurological diseases. They may be
selective or may also inhibit the ACE and neutral endo-
peptidase [49]. ET degradation has been achieved by means
of neutral endopeptidase transfection in ovarian carcinoma
cells. NEP is a cell surface aminopeptidase with a ubiquitous
expression and is able to degrade various bioactive peptides,
including ET-1 [50].
Among all these options, the ET receptor blockade has
reached the most advanced phases of preclinical and clinical
drug development. Several small molecules functioning as
ETAR antagonists have provided a clearer understanding of
the physiologic role of ET-1 and its effects on ET receptor-
mediated signal transduction in tumor development and
progression. Atrasentan and ZD-4054 are the most potent
and selective ETAR antagonists. They are orally bioavailable.
For this reason, they are well qualified for clinical development
in cancer treatment.
Atrasentan is able to inhibit effectively cell proliferation and
VEGF secretion both in ovarian carcinoma cell lines and
primary cultures. This action of atrasentan can be translated
into biological effects such as reduction of microvessel density,
VEGF and MMP-2 expression and increase in the percentage
of apoptotic tumor cells.
Its combination with paclitaxel seems to be synergistic
because of the enhancement of antitumor, proapoptotic
and antiangiogenic effects. These phenomena may be
explained by the sensitization to paclitaxel-induced apoptosis
by the ETAR blockade [51]. Moreover, the synergistic action of
chemotherapy and ETAR antagonists is supported by the
finding of specific higher expression of ETAR gene in post-
chemotherapy samples of primary ovarian tumors [52]. In
breast carcinoma, the overexpression of ETAR has induced
resistance to chemotherapy. Some authors have suggested the
use of the evaluation of ETAR expression levels to predict the
responsiveness of cancer patients to chemotherapy [53].
Atrasentan has induced tumor growth inhibition in xeno-
grafts of cervical carcinoma cells. This effect has been observed
with just two cycles of treatment [54]. The additive effects of
paclitaxel when combined with atrasentan have been obtained
both in cervical carcinoma models [30] and in ETAR-
overexpressing prostate cancer cells [43]. They are associated
with a lower cell viability and a higher apoptotic rate.
In prostate cancer, the proliferative action of exogenous
ET-1 is blocked by ETAR antagonists. This observation has
been explained by the finding of bone–tumor interaction
impairment through the direct inhibition of osteoblasts.
The role of ET receptor antagonists in prostate cancer is
also supported by the finding of a high expression of ETAR,
both in primary and metastatic tumors, which is associated
with advanced tumor stage and grade.
ETAR expression is also correlated with survival and might
predict distant metastases in nasopharyngeal carcinoma
(NPC) [55]. The inhibition of NPC cell proliferation by
atrasentan depends on ETAR expression. In this type of tumor,
atrasentan has also induced more evident apoptotic effects
when combined with cytotoxic drugs such as cisplatin and
5-fluorouracil in xenograft models. The xenografts of meta-
static tumors have demonstrated a role for atrasentan in
reducing metastases to the lung from both nasopharyngeal
and bladder cancers [56,57].
Several other ET receptor antagonists have also been
studied in preclinical cancer models.
Zibotentan (ZD-4054) is an orally active specific ETAR
antagonist. ETAR blockade by zibotentan inhibits ET-1-
induced mitogenic effects, while the ETBR antagonist, BQ
788, is ineffective. Zibotentan is able to inhibit the prolifer-
ative activity of ET-1 in ovarian carcinoma cells [58]. The
combination of zibotentan and paclitaxel produces additive
effects on the reduction of ETAR-driven angiogenesis and
invasive mediators, such as VEGF, COX-1/2 and MMP.
Forty percent of mice bearing human ovarian cancer remained
tumor-free, suggesting a possible clinical role of zibotentan as
monotherapy or in combination with cytotoxic drugs [59]. In
ovarian carcinoma xenografts, zibotentan has enhanced the
efficacy of gefitinib, achieving partial (82%) or complete
tumor regression. A cross-talk between the EGFR and
ETAR pathways has been documented together with the
evidence of decreased vascularization, Ki-67, MMP-2,
VEGF, MAPK and EGFR, and enhanced E-cadherin
expression [60].
Bosentan, a dual ET receptor antagonist targeting ETAR
and ETBR, has therapeutic indications for cardiovascular
diseases. In a breast carcinoma cell metastasis model, bosentan
has shown inhibition of tumor growth, neovascularization and
bone metastasis. In melanoma xenografts, bosentan has
enhanced the effects of alkylating agents, such as dacarbazine,
when a combination treatment was delivered [61].
A-182086 is another dual antagonist. It can inhibit tumor
growth by blocking proliferation not only of tumor cells but
also of endothelial cells expressing ETBR. It has shown a
potential role in Kaposi sarcoma treatment because of simul-
taneous interference with cell proliferation, invasiveness and
angiogenesis [62,63].
BQ788 is a peptide ETBR antagonist which inhibits growth
and induced death of melanoma cells in vitro and in vivo [64].
A-192621 is a specific ETBR antagonist studied in xeno-
grafts of human melanoma cells. It suppresses HIF-1a accu-
mulation, tumor growth, neovascularization and VEGF and
MMP-2 expression [65].
6. Competitive environment
The pharmaceutical development of ET receptor antagonists
has derived from the observation of the prominent role of the
ET-1 axis in cardiovascular diseases. ABT-627 is an agent
developed by Abbott Laboratories; it is also known as atra-
sentan and marketed under the brand name of Xinlay. It is
one of the most potent and selective ETAR antagonists. Its
Anti-endothelin drugs in solid tumors
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effects on the ET-1 blockade were discovered in in vitro and
in vivo models for cardiovascular diseases and malignancies.
Atrasentan seems qualified for clinical use because it is orally
bioavailable and has a half-life of 25 h, thus, allowing daily
delivery. It has produced mild adverse effects in healthy
volunteers [66], for example, transient headache, rhinitis
and nausea, which appear to be associated with atrasentan
action on the inhibition of the function of ET-1 as a
vasoconstrictor. However, no liver or hematological toxicity
has been reported.
Atrasentan is able to increase plasma levels of ET-1 due
to the blockade of ETB. Zibotentan is the only ET receptor
antagonist in clinical development that targets ETAR
without inhibition of ETBR at doses under clinical
investigation [67]. Table 1 reports a description of the
main features of the agents of this class studied for
anticancer treatment.
Prostate cancer patients have been identified as the best
clinical setting for testing the safety and efficacy of ET
receptor antagonists. Preclinical findings, in fact, have
already shown a clear role of ET-1 in the development
and progression of prostate carcinoma.
6.1 Atrasentan
Two Phase I clinical trials were designed to treat hormone
refractory prostate cancer patients with escalating doses of
atrasentan ranging between 2.5 and 95 mg orally for 28 days.
In one of the two studies, headache was found to be the dose-
limiting toxicity obtained at 75 mg, while in the other study
the maximum tolerated dose was not reached. As previously
found in healthy subjects, headache, rhinitis and peripheral
edema were the most common side effects [68,69]. Even though
prostate specific antigen (PSA) response was not the aim of the
study, 68% (15/22) of patients achieved a reduction of PSA
levels ranging between 5 and 95%. Doses of atrasentan
showed no correlation with PSA declines.
Ten patients in the same study were affected by pain which
needed treatment with opioids. In all, 70% of them experi-
enced pain reduction evaluated by VAS. Preclinical findings
indicated the particular effect of ET-1 in inducing hyperalge-
sia and pain through cutaneous injection [70,71]. This phe-
nomenon is mediated by the excitation of ETAR-mediated
nociceptors. On the other hand, ETBR activation induces
analgesia by the release of b-endorphin and the activation of
the opioid pool [72].
These effects of atrasentan in controlling cancer pain
were studied in one Phase II clinical trial, double-blind and
placebo-controlled; for hormone-refractory metastatic pros-
tate cancer, patients were affected by pain needing opioid
supplementation. The primary end point of this particular
study was to evaluate the rate of pain relief after 12 weeks of
treatment. No statistically significant difference was observed.
A trend toward cancer pain amelioration with control of
analgesic consumption was obtained only in the group of
patients treated with 10 mg atrasentan. In the same group, a
statistical significance was observed in the improvement of
‘pain interference with relations with other people’ (p = 0.031)
and ‘worst pain in the last 24 h’ (p = 0.030). This finding
suggests a possible specific role of atrasentan to increase the
quality of life [73].
A subsequent Phase II trial investigated the antitumor
activity as identified through PSA reductions observed in
previous Phase I studies. This second trial, double-blind
and placebo-controlled, evaluated the effect on time-to-
progression prolongation. Asymptomatic hormone-refrac-
tory metastatic prostate cancer patients were divided into
three arms, those treated with a placebo, with 2.5 mg and
with 10 mg atrasentan. In the evaluable set, but not in the
intent-to-treat analysis, a statistically significant difference
in the delay of disease progression was seen between placebo
and 10 mg atrasentan groups (p = 0.021).
Overall survival analysis in this study found no significant
advantage in the atrasentan arms versus placebo. This result
seems to be due to the confounding effect of the crossover
toward atrasentan treatment administered to placebo group
patients. Survival advantage proved to be significant when
atrasentan treatment groups were combined into a single arm
achieving HR = 0.69 [68].
Tolerabilty profile included mild toxicity with headache,
rhinitis and edema as the most common side effects.
The markers of bone deposition (alkaline phosphatase,
bone alkaline phosphatase) and bone resorption (N-telo-
peptides, C-telopeptides and deoxypyridinoline) were eval-
uated in the same Phase II trial with atrasentan, which
showed a dose-dependent effect on the stabilization of these
markers and a clear trend toward the improvement of the
bone scan index was found in the 10 mg arm [74]. These
findings agree with preclinical data regarding the role of the
ET-1 axis in bone formation. Osteoblasts have shown the
expression of high affinity ETAR receptors and strong
response to ET-1 stimulation leading to the osteoblastic
proliferation associated with metastatic breast and prostate
cancers [44,75]. In vivo models of bone metastasis have
clarified the role of ETAR in osteogenesis by means of
the use of ETAR antagonists [46].
On the basis of the clinical findings of a Phase II trial
involving disease progression delay, a Phase III clinical study
(M00-211) was designed to verify the ability of atrasentan to
duplicate time to progression in asymptomatic hormone-
refractory metastatic prostate cancer patients. These were
grouped into two arms, placebo and 10 mg atrasentan.
Secondary end points were PSA response rate, markers of
bone metabolism and quality of life. As in the Phase II
M96-594 trial, time to progression was significantly delayed
in the evaluable set analysis but not in the intent-to-treat
analysis (p = 0.007 vs 0.091). All the secondary end points
showed a significant favor trend for the 10 mg atrasentan arm.
Moreover, in the 10 mg atrasentan group, a stratification of
this trial data made it possible to observe a significant
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prolongation of time to progression in the subgroup of
patients with bone metastases independently of soft tissue
metastases [76]. This finding suggests interesting implications
regarding the clinical use of atrasentan in CRPC due to the
large number of patients (85%) with bone metastasis.
Subsequently, another Phase III trial was performed in
nonmetastatic hormone-refractory prostate cancer patients
with no radiographic evidence of metastases but rising PSA
levels. These were randomized to receive 10 mg atrasentan or
placebo. The primary end point, time to progression defined
as the time to the onset of metastases, was not achieved.
A favoring trend for atrasentan was highlighted through the
evaluation of the secondary end points: time to PSA progres-
sion, change in bone alkaline phosphatase levels, PSA dou-
bling time and overall survival. Large geographic differences in
the median time to progression were observed, which implies
that trial conduct may have influenced the results. A more
adequate study design should, therefore, be considered [77].
Atrasentan has also been studied in clinical trials involving
the combination with other antineoplastic agents. A Phase II
study for the comparison between atrasentan alone and its
combination with zoledronic acid was designed to evaluate
bone turnover markers in men with bone metastases from
prostate cancer. There is no evidence for additive or synergistic
effects of combination treatment on these markers [78].
Preclinical data regarding the combination therapy with
taxanes and atrasentan have already suggested a potential role
in the treatment of refractory malignancies. In metastatic
CRPC patients, a Phase I/II trial investigated the feasibility
of docetaxel at doses ranging from 60 to 75 mg/m2 every
21 days, with daily oral atrasentan 10 mg starting on day 3
until evidence of disease progression or unacceptable toxicity.
The maximum tolerated dose of docetaxel in this regimen is
70 – 75 mg/m2. Overall survival and progression-free survival
are similar to that normally obtained with docetaxel and
prednisone. The PSA response rates are slightly lower than
expected. A Phase III trial to compare this combination with
docetaxel and prednisone had already been designed and is still
ongoing [79].
In advanced NSCLC, 10 mg/day atrasentan plus standard
paclitaxel–carboplatin combination have been investigated for
safety and pharmacokinetics. They appear to be well tolerated,
without pharmacokinetic interaction of paclitaxel and atra-
sentan. Efficacy and survival have proved to be similar to those
already observed in studies involving the use of chemotherapy
alone in advanced NSCLC patients [80]. Phase III trials and
other combination regimen trials should also be designed.
6.2 Zibotentan
Zibotentan, when studied in asymptomatic or mildly symp-
tomatic hormone-refractory prostate cancer patients with
bone metastases, obtained similar results. Primary end point
(time to progression) was not achieved, but advantage in
overall survival was seen in both 10 and 15 mg zibotentan
arms [81].
A subsequent Phase I study evaluated escalating doses of
zibotentan ranging between 10 and 200 mg/day p.o. in
Table 1. Endothelin receptor antagonists studied in clinical trials for cancer treatment.
Compound Company Mechanism of action Indication Stage of
development
Side effects
Atrasentan
(ABT-627,
Xinlay)
Abbott, USA ETAR antagonist
Reduction of microvessel density,
VEGF and
MMP-2 expression and increase
of the percentage of apoptotic
tumor cells
Castration-resistant
prostate cancer
Phase III trial Headache,
rhinitis and
nausea
Zibotentan
(ZD-4054)
AstraZeneca, UK ETAR antagonist
Inhibits ET-1-induced mitogenic
effects
The combination with paclitaxel
produces additive effects on
the reduction of ETAR-driven
angiogenesis and invasive
mediators
Castration-resistant
prostate cancer
Phase III trial Headache,
peripheral
edema, fatigue,
nasal congestion
and nausea
Bosentan Hoffmann-La
Roche,
Switzerland
Dual ET receptor antagonist
targeting
ETAR and ETBR
Inhibits tumor growth,
neovascularization and bone
metastasis
Melanoma Phase II trial Headache,
fatigue, nausea,
back pain and
abnormal
hepatic function
ET: Endothelin; ETAR: Endothelin A receptor; ETBR: Endothelin B receptor.
Anti-endothelin drugs in solid tumors
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Table 2. Clinical studies with ETAR antagonists.
Citation Phase Patients Agents Schedule Results
Atrasentan
Zonnenberg
2003 [69]
I Metastatic CRPC Atrasentan A 2.5 – 95 mg/day
p.o.
No dose-limiting adverse
events observed up to
95 mg
The most common adverse
events were rhinitis,
headache and peripheral
edema
Armstrong
2008 [79]
I/II Metastatic CRPC Atrasentan
+ docetaxel
A 10 mg/day p.o.
+ D every 3 weeks
i.v. 60 – 75 mg/m2
Overall survival and
progression-free survival
are comparable to that
seen with docetaxel and
prednisone, whereas the
rates of PSA decline are
slightly lower than
expected
Drug-related grade 3 – 4
toxicities included
neutropenia (50 – 63%)
and febrile neutropenia
(16 – 25%)
Chiappori
2008 [80]
I/II Advanced NSCLC Atrasentan +
carboplatin +
paclitaxel
A 10 mg/day p.o.
+ C every 3 weeks
i.v. AUC6 + P every
3 weeks i.v.
225 mg/m2
Atrasentan plus
paclitaxel–carboplatin was
safe and well tolerated,
with no apparent
paclitaxel–atrasentan
pharmacokinetic
interaction
Efficacy and survival in
advanced NSCLC were
comparable with studies of
chemotherapy alone
Carducci
2003 [68]
II Metastatic CRPC Atrasentan
vs placebo
A 2.5 mg/day p.o.
A 10 mg/day p.o.
Placebo
Median TTP prolongation
Headache, peripheral
edema and rhinitis were
primary side effects
Michaelson
2006 [78]
II Prostate cancer
with bone
metastases
Atrasentan +
zoledronic acid
A 10 mg/day p.o.
A 10 mg/day p.o. +
ZA every 4 weeks
i.v.
No evidence for additive or
synergistic effects of
combination therapy with
atrasentan and zoledronic
acid on bone turnover
markers
Commonly observed
adverse effects were
edema, rhinitis, fatigue
and shortness of breath
Carducci
2007 [76]
III Metastatic CRPC Atrasentan vs
placebo
A 10 mg/day p.o.
Placebo
Atrasentan did not delay
disease progression in men
with metastatic CRPC
despite evidence of
biologic effects on markers
of disease burden
A: Atrasentan; B: Bosentan; b.i.d.: Twice a day; C: Carboplatin; CRPC: Castration-resistant prostate cancer; D: Docetaxel; ETAR: Endothelin A receptor;
i.v.: Intravenous; MWTD: Maximum well-tolerated dose; P: Paclitaxel; p.o.: Per os; PSA: Prostate specific antigen ; TTP: Time to progression; Z: Zibotentan;
ZA: Zoledronic acid.
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metastatic CRPC patients. The maximum well-tolerated dose
for zibotentan was 15 mg/day p.o. Dose-limiting toxicity was
similar to that reported for other drugs of this class. Some
patients experienced prolonged stable disease, suggesting that
new methods are needed to test antitumor activity [82].
Phase III studies with zibotentan in the same setting of
patients are ongoing.
6.3 Bosentan
Bosentan, the dual ETAR/ETBR antagonist, was also studied
in a Phase II trial with metastatic melanoma patients. No
tumor responses were obtained, but disease stabilization was
found in about 20% of patients suggesting the need for further
investigation in combination with other anticancer
drugs [83]. Table 2 summarizes all the clinical trials with ET
receptor antagonists studied for cancer treatment.
7. Conclusions
ETs belong to a family of proteins with regulatory activity in
different cellular pathways, including cell growth, survival,
invasion and angiogenesis. ET-1, which mainly exert their
function on the ETAR, has shown a role in the various phases
of carcinogenesis and cancer progression of different tumor
types. Preclinical studies have demonstrated the capability of
ET antagonists in inhibiting tumor cell proliferation, invasive-
ness and new vessel formation, as well as their effects on
osteogenesis and cancer-related pain. The clinical investi-
gation of an orally bioavailable ET antagonist, atrasentan,
has suggested its benefit in PSA progression, markers of bone
turnover, and pain in men with prostate cancer, but improve-
ment in time to progression and overall survival has not yet
been demonstrated with sufficient statistical significance,
perhaps because of the small number of patients included in
Table 2. Clinical studies with ETAR antagonists (continued).
Citation Phase Patients Agents Schedule Results
Nelson
2008 [77]
III Nonmetastatic CRPC Atrasentan vs
placebo
A 10 mg/day p.o.
Placebo
Although the primary end
point was not achieved,
large regional differences
in TTP were noted,
suggesting that trial
conduct may have
influenced the results
Zibotentan
James
2009 [81]
II Metastatic CRPC Zibotentan vs
placebo
Z 10 mg/day p.o.
Z 15 mg/day p.o.
Placebo
The primary end point of
TTP was not achieved in
this study, but an
improvement was seen in
overall survival in both
active treatment arms
Adverse events were in line
with the expected
pharmacologic effects of
an ETAR antagonist
Schelman
2009 [82]
I Metastatic CRPC Zibotentan Z 10 – 200 mg/day
p.o.
The MWTD for zibotentan
was 15 mg
Dose-limiting toxicity was
similar to that reported for
other drugs of this class
Some patients experienced
prolonged stable disease
Bosentan
Kefford
2007 [83]
II Metastatic
melanoma
Bosentan B 500 mg/day p.o.
b.i.d.
Benefit in disease
stabilization
The most frequent adverse
events were headache,
fatigue, nausea, back pain
and abnormal hepatic
function
A: Atrasentan; B: Bosentan; b.i.d.: Twice a day; C: Carboplatin; CRPC: Castration-resistant prostate cancer; D: Docetaxel; ETAR: Endothelin A receptor;
i.v.: Intravenous; MWTD: Maximum well-tolerated dose; P: Paclitaxel; p.o.: Per os; PSA: Prostate specific antigen ; TTP: Time to progression; Z: Zibotentan;
ZA: Zoledronic acid.
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the clinical trials. This class of drugs seems quite promising,
above all for CRPC patients. Nevertheless, we should define
their exact role in different cancer treatments by means of
future clinical trials.
8. Expert opinion
The ET axis, which includes the biological functions of the
ETs and their receptors, has played a physiological role in
normal tissue, acting as a modulator of vasomotor tone, tissue
differentiation and development, cell proliferation and hor-
mone production. Interestingly, it also functions in the growth
and progression of various tumors. In vitro and in vivo studies
have suggested that it can trigger signaling pathways impli-
cated in various hallmarks of cancer, including aberrant cell
proliferation, adhesion, migration, invasion, angiogenesis and
antiapoptotic activity.
Several researchers have identified the blockade of the ET-1
receptor as a promising therapeutic approach.
Preclinical findings have highlighted the fact that ET-1
receptor antagonists enhance the efficacy of cytotoxic drugs.
When ETAR is blocked by its antagonists, the cancer cells are
sensitized to the apoptotic potential of chemotherapeutics
drugs. The finding of sensitization to paclitaxel is an
example of this phenomenon obtained by ovarian and cervical
carcinoma preclinical models.
Atrasentan – one of the most potent and selective ETAR
antagonists – has been the most effectively studied, because it
has been included in two Phase III clinical trials as mono-
therapy and Phase I/II combination trials with chemotherapy.
It has shown a quite amazing tolerability profile and even the
means of administration – oral – would allow a wide appli-
cability if its preliminary efficacy results are subsequently
confirmed. Time to progression, which is the primary end
point of the Phase III trials with atrasentan, has been achieved
only in the evaluable set of metastatic patients. No statistically
significant efficacy has been observed in the intent-to-treat
analysis. Overall survival, one of the secondary end points, has
confirmed a non-positive trend in favor of patients treated
with atrasentan independently of its dose. All these results
suggest that more effective clinical trials are required in order
to evaluate ETAR antagonists.
To date, the treatment of prostate cancer patients is the only
clinical setting to be extensively studied for therapy with
atrasentan. Unsatisfactory results have been obtained from
a Phase II trial with bosentan in metastatic melanoma patients.
The improved characterization of the ET-1 axis will
provide a valid target for more promising molecular treat-
ment strategies to combine with known anticancer drugs.
The synergistic action of ZD-4054 and gefitinib on tumor
burden reduction is the best demonstration of this
therapeutic potential.
The choice of the most adequate end point to define the
clinical efficacy of these drugs remains the most controversial
feature. Statistical power, baseline characteristics of patients
and pharmaceutical doses are the parameters to emphasize in
order to reach a definite understanding of the role of these new
agents in cancer treatment.
Combination clinical trials with chemotherapy or other
anticancer agents in various malignancies are needed. These
studies will found a proper rationale in the results of the
combination Phase I/II trials with atrasentan and standard
chemotherapeutic drugs in prostate and lung cancers.
Nevertheless, different end points, not only clinical but also
molecular, should be identified in order to reach a better
understanding of the most appropriate application of these
agents in the treatment of solid tumors.
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